drugset / Trial / NCT06648850
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
Phase 2/3
Not yet recruiting
1120 enrolled
Applied Biology, Inc.
Daniel Alain, Inc. · collabFollea International Limited · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth
Timeline
- Start
- 2026-05-01
- Primary completion
- 2027-03-19
- Completion
- 2027-04-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-001 | Unknown | 2.5 % | Topical |
| Subject | Intact Pro | Unknown | — | Topical |
| Subject | Phenylephrine | Small molecule | 0.25 % | Topical |
| Subject | Phenylephrine | Small molecule | 2.5 % | Topical |